Skip to main content
NIKI
NASDAQ Industrial Applications And Services

Niki BioSolutions Files Audited DiamiR Financials and Pro Forma Statements, Confirming Going Concern

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Negative
Importance info
8
Price
$8.58
Mkt Cap
$6.987M
52W Low
$6
52W High
$44.7
52W Position info
43% above low
Off High info
81% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

NIKI sits 43% above its 52-week low of $6 on light trading volume (0.4× avg).

Summary

Niki BioSolutions filed audited DiamiR financials and pro forma combined statements showing substantial losses and a going concern warning, with the merger valued at $17.48M including $8.24M in patents and $6.78M in IPR&D.


Key Events · Earnings and Guidance · NIKI

  • Audited DiamiR Financials Filed

    DiamiR's audited financials for fiscal years ended May 31, 2026 and 2025 show net losses of $659,936 and $743,235, respectively, with a going concern explanatory paragraph from CBIZ CPAs P.C.

  • Pro Forma Combined Losses

    Unaudited pro forma combined statements show net loss attributable to Niki of $2.05M for six months ended June 30, 2026 and $3.60M for year ended December 31, 2025.

  • Purchase Price Allocation

    Preliminary allocation of $17.48M total consideration: $8.24M patents, $6.78M in-process R&D, $1.58M tradename, $1.08M goodwill, and $197,761 other intangibles.

  • Convertible Notes Converted

    Niki's $3.51M convertible notes converted at $24.20/share into 144,979 shares; DiamiR's $1.31M notes converted into 409,925 DiamiR shares included in the 1,979,216 shares issued to DiamiR stockholders.


Analysis · NIKI · Industrial Applications And Services

Investors assessing the post-merger company's financial health now have the detailed numbers behind the going concern warning. This amendment delivers the audited financial statements of DiamiR and the unaudited pro forma combined financials for the merged entity. The auditor's report includes a going concern explanatory paragraph, and the pro forma statements show combined net losses of $2.05M for the six months ended June 30, 2026 and $3.60M for the year ended December 31, 2025. The preliminary purchase price allocation values DiamiR's patents at $8.24M, IPR&D at $6.78M, and goodwill at $1.08M. While the going concern warning was already disclosed in a separate 8-K earlier today, these detailed financials quantify the combined entity's losses and the significant intangible asset values, which are material for investors.

At the time of this filing, NIKI was trading at $8.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7M. The 52-week trading range was $6.00 to $44.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NIKI - Latest Insights

NIKI
Aug 21, 2026, 5:15 PM EDT
Source: Reuters
Importance Score:
8
NIKI
Aug 21, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
NIKI
Aug 07, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
NIKI
Jul 24, 2026, 4:31 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8